The advent of MRI-guided prostate biopsy has revolutionised this process. By using high-resolution Magnetic Resonance Imaging (MRI) before the procedure, urologists can now identify specific areas of concern and target them with millimetre precision, ensuring a more accurate diagnosis while reducing the discomfort of unnecessary sampling.

The Prevention: Lifestyle Tips

While you cannot change your genetics, you can influence the health of your prostate environment:

Mr. Collins Approach

While many clinics might move straight from a raised PSA to an invasive biopsy, by integrating this advanced biomarker assessment with MRI interpretation and PSA density, Mr Collins ensures that patients are never rushed into over-treatment for insignificant conditions, nor are they left in the dark about aggressive biology. 

Book an Appointment

FAQs

Based in Manchester and Cheshire, Mr Gerald Collins is currently accepting private consultations for the assessment of kidney masses, haematuria, and general urological concerns. With 29 years of experience, he provides the clarity and expertise needed to move from uncertainty to a confident treatment plan.

The post MRI-Guided Prostate Biopsy: Precision in Diagnosis appeared first on Gerry Collins Urology.

The Stockholm3 (STHLM3) model represents a major shift toward precision medicine. It is an advanced, risk-based blood test designed to refine detection by combining protein biomarkers, genetic markers, and clinical data into a sophisticated algorithm. By looking beyond a single number, it provides a much clearer picture of an individual’s true biological risk.

Relevant Fact:

Clinical studies involving over 90,000 men have demonstrated that the Stockholm3 test can reduce unnecessary biopsies by up to 52 percent while detecting nearly double the number of aggressive cancers in men with low PSA values (between 1.5 and 2.9 ng/ml) who might otherwise have been missed.

Symptoms

Early-stage prostate cancer often presents no symptoms at all. However, as the prostate enlarges, whether due to benign growth (BPH) or malignancy, you may notice:

• An increased urgency to urinate, particularly at night (nocturia).
• A weak or interrupted urinary flow.
• Difficulty starting to urinate or straining to empty the bladder.
• The presence of blood in the urine or semen (haematuria).
• Persistent pain in the back, hips, or pelvis, which can sometimes indicate more advanced disease.

If you experience these symptoms, it is essential to seek a specialist evaluation rather than relying solely on a standard PSA result.ent.

Mr. Collins Approach

While many clinics might move straight from a raised PSA to an invasive biopsy, Mr. Collins uses the Stockholm3 test as a critical “reflex test”. By integrating this advanced biomarker assessment with MRI interpretation and PSA density, he ensures that patients are never rushed into over-treatment for insignificant conditions, nor are they left in the dark about aggressive biology. 

Book an Appointment

Causes & Risk Factors

While the exact cause of most kidney cancers remains unclear, certain factors can increase your risk:

FAQs

Based in Manchester and Cheshire, Mr Gerald Collins is currently accepting private consultations for the assessment of kidney masses, haematuria, and general urological concerns. With 29 years of experience, he provides the clarity and expertise needed to move from uncertainty to a confident treatment plan.

The post Understanding the Stockholm3 Test appeared first on Gerry Collins Urology.

1. Confirming the Trend

The first step following an abnormal PSA result (generally >4.0 ng/mL, though age-adjusted) is often repeat testing.

• Confirmation: NCI and AUA guidelines recommend repeating the PSA test in 6 to 8 weeks to account for transient elevations caused by recent exercise, ejaculation, or minor infection.
• PSA Change: Recent research suggests that if a repeat test shows a decline of >20%, the risk of clinically significant cancer is lower, and a biopsy may potentially be avoided.
• PSA Velocity: While a rapidly rising PSA is a red flag, the AUA cautions that “PSA velocity” (the rate of change over time) should not be the sole reason for a biopsy; it must be considered alongside other risk factors.

2. Risk Assessment and “PSA Density”

To improve diagnostic accuracy, clinicians look beyond the total PSA number:

• PSA Density: This is the PSA level divided by the volume of the prostate (measured via ultrasound or MRI). A higher PSA density is a stronger predictor of cancer than the PSA level alone, especially in men with large prostates.
• Clinical Findings: A suspicious finding during a Digital Rectal Exam (DRE), such as a firm lump or irregularity, significantly increases the urgency for further investigation regardless of the PSA level.
• Risk Calculators: Tools that incorporate age, race, and family history help determine the probability of “clinically significant” prostate cancer (Grade Group 2 or higher).

3. The Role of Imaging (mpMRI)

Before proceeding to a biopsy, advanced imaging is now frequently used as a “gatekeeper” or triage tool.

• mpMRI (Multiparametric MRI): The European Association of Urology (EAU) and NCI support using mpMRI to identify suspicious areas within the prostate.
• Avoiding Biopsy: If an MRI is clear (PI-RADS 3 or less) and other risk factors are low, a doctor and patient may choose to forgo a biopsy and continue observation.
• Targeted Biopsy: If the MRI identifies a suspicious lesion (PI-RADS 4 or 5), it allows for a “targeted biopsy,” where needles are precisely guided to the area of concern, increasing the likelihood of detecting aggressive cancer.

4. When is a Biopsy Appropriate?

A prostate biopsy is the only definitive way to diagnose cancer. It is generally recommended when:

• The PSA remains elevated after a confirmatory test.
• The PSA density is high.
• The mpMRI shows suspicious lesions.
• A DRE reveals an abnormal lump.
• Shared Decision-Making: For men aged 55–69, the decision must weigh the benefit of early detection against the risks of the procedure (infection, bleeding) and the potential for “overdiagnosis” of slow-growing tumours that may never cause harm.

Summary Checklist for Further Testing

Mr Collins Approach

Mr Gerry Collins views a PSA result not as a definitive verdict; he incorporates your prostate volume, your age, and the Free to Total PSA ratio to build a risk-stratified map. By using advanced tools like the Stockholm3 biomarker test and MRI-guided interpretations, he filters out the benign causes of PSA elevation, such as inflammation or BPH, ensuring that only those who truly need an intervention proceed to biopsy. 

Book an Appointment

Based in Manchester and Cheshire, Mr Gerald Collins is currently accepting private consultations for the assessment of kidney masses, haematuria, and general urological concerns. With 29 years of experience, he provides the clarity and expertise needed to move from uncertainty to a confident treatment plan.

The post When Further Tests are Needed: Guidance on Prostate Imaging and Biopsy appeared first on Gerry Collins Urology.